A kind of traditional Chinese medicine composition for treating stable chronic obstructive pulmonary disease

Abstract

The invention provides traditional Chinese medicine composition for treating the stationary-phase COPD (chronic obstructive pulmonary disease). The composition comprises raw materials in parts by weight as follows: 47 parts of codonopsis radix, 59 parts of light wheat, 35 parts of fried largehead atractylodes rhizome, 23 parts of prepared pinellia tuber, 47 parts of dried tangerine peel, 35 parts of perilla fruit, 35 parts of divaricate saposhnikovia root, 35 parts of poria cocos, 59 parts of raw coix seed, 35 parts of honey-fried common coltsfoot flower, 35 parts of baical skullcap root, 35 parts of bulbus fritillariae pallidiflorae and 35 parts of honey-fried loquat leaf. The traditional Chinese medicine composition can prolong the second-time acute exacerbation time interval of a COPD patient by 77.68 days, decrease acute exacerbation times by 1.46 times per half a year, shorten the acute exacerbation duration by 2.93 days, decrease mMRC and CAT scores, improve clinical symptoms such as coughing, expectoration, shortness of breath, spontaneous perspiration, lacking in strength and the like, and enhance the exercise tolerance (that is, the 6MWD is increased). The composition has no side effect in a taking process of the clinical patient, so that the composition is a safe and effective prescription for treating the stationary-phase COPD.

Description

Technical field [0001] The invention relates to a traditional Chinese medicine composition for treating stable chronic obstructive pulmonary disease. Background technique [0002] Chronic obstructive pulmonary disease (COPD) is a disease characterized by airflow limitation. COPD patients accounted for 3% of people aged 15 years and over in my country. It is the first cause of death in rural areas and the first in the World Health Organization’s assessment of the burden of disease in my country. Bit. Studies by the World Bank and WHO show that COPD was the 12th most lethal and disabling disease in the world in 1990, but it will become the 3rd most lethal and disabling disease in the world by 2020. Although countries all over the world have invested a lot of manpower and material resources in COPD research, and formulated corresponding diagnosis and treatment standards, the prevalence, mortality, and disability rate of COPD and the resulting burden of disease in the family and soci...

AI Technical Summary

Problems solved by technology

[0003] At present, there is no definite curative effect of the drugs for the treatment of COPD in the stable stage, and there are no therapeutic drugs that have undergone formal clinical trials on the market. The traditional Chinese medicines currently used in the clinical treatment of COPD in the stable stage are mostly decoctions and non-decoction powders , the preparation process of the decoction is complicated, and the taste is bitter and astringent when taken, the taste is poor, and it has certain irritation to the gastrointestinal tract

Images